LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix, but has underperformed recently. SCD trades at an 8.68% discount to NAV, yet remains ...
Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A growing landscape for sickle cell disease (SCD) treatments, a growing relationship between the companies, and the potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback